Adjuvant pembrolizumab improves overall survival in patients with RCC

IF 81.1 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2024-04-29 DOI:10.1038/s41571-024-00901-2

Peter Sidaway

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

pembrolizumab辅助治疗可提高RCC患者的总生存率

在III期KEYNOTE-564试验中，与安慰剂相比，抗PD-1抗体pembrolizumab的辅助治疗可显著改善切除的非转移性中高危肾细胞癌（RCC）患者的无病生存期（DFS）。现在，这项试验的最新进展证实，pembrolizumab也能改善总生存期（OS）。共有994名患者被随机分配（1:1）接受pembrolizumab或安慰剂治疗。OS 是次要终点。此前，以24个月为分界点，DFS（主要终点）的改善具有统计学意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.

期刊最新文献

A new standard of care for leiomyosarcoma Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance Vorasidenib: a new hope or a false promise for patients with low-grade glioma? New clinical trials in CUP and a novel paradigm in cancer classification The age of foundation models